AdaptHealth Posts Mixed Q3 Earnings, Revises Annual Guidance

  • AdaptHealth Corp AHCO delivered Q3 revenue of $756.5 million, +15.8% Y/Y, beating the consensus of $737.94 million.
  • Adjusted EBITDA reached $160.2 million, +2.5% Y/Y.
  • Steve Griggs, Chief Executive Officer, commented, "We delivered another solid quarter as we continued to capitalize on strong demand in our HME and Sleep product lines with CPAP patient set-ups at or near record levels each month of the quarter, and our diabetes product line once again posting double-digit growth."
  • The company reported EPS of $0.11, down from $0.20 a year ago and the consensus of $0.31.
  • Cash flow from operations was $107 million.
  • Guidance: AdaptHealth revised FY22 sales to $2.95-$3.01 billion compared to $2.84 - $3.04 billion expected earlier versus the consensus of $2.95 billion.
  • It has tightened the adjusted EBITDA forecast to $620-$650 million from $615-$675 million.
  • Price Action: AHCO shares are down 1.99% at $20.64 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!